ICN's Oxsoralen-Ultra
Executive Summary
New dosage form of methoxsalen is an encapsulated liquid, which ICN says has an improved success rate over the crystalline form of methoxsalen due to its "increased bioavailability and absorption, earlier photosensitization onset time and increased pharmacokinetic reliability." New anti-psoriatic formulation reduces the number of annual PUVA (psoralen ultraviolet-A) treatments from 249 to 20 and "turns most PUVA-resistant patients into therapeutic successes," ICN says.